Abstracts tagged "Myositis"

Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 1841 • ACR Convergence 2021
Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases
Louisa-Marie Mockenhaupt¹, Ramona Dolscheid-Pommerich¹, Charlotte Behning¹, Birgit Stoffel-Wagner², Peter Brossart¹ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²University Hospital Bonn, Bonn
Background/Purpose: Antinuclear antibodies (ANA) are serological markers for the presence of connective tissue diseases [1]. In some patients, a pattern can be detected in ANA…
Abstract Number: 0001 • ACR Convergence 2021
Autoantigenic Properties Indicated for the Entire Aminoacyl tRNA Synthetase Family in Idiopathic Inflammatory Myopathies
Charlotta Preger¹, Antonella Notarnicola¹, Cecilia Hellström², Edvard Wigren¹, Catia Cerqueira³, Peter Nilsson², Ingrid E Lundberg¹, Helena Persson⁴, Susanne Gräslund¹ and Per-Johan Jakobsson⁵, ¹Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ²Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ³4Dcell, Montreuil, France, ⁴Drug Discovery and Development Platform, SciLifeLab & School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), Solna, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoantibodies are thought to play a key role in the pathogenesis of idiopathic inflammatory myopathies (IIM). However, 40% of IIM patients, even those with…
Abstract Number: 0698 • ACR Convergence 2021
Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue
Andrew Zlobin, Peter Pytel and Vladimir Liarski, University of Chicago, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIM) – dermatomyositis (DM), polymyositis, and inclusion body myositis - are poorly understood autoimmune muscle disorders. Isolation of relevant immune cell…
Abstract Number: 0719 • ACR Convergence 2021
Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies
Gözde Kübra Yardımcı¹, Arzu Taghiyeva², Enes Erul², Bayram Farisogulları³, Levent Kilic¹ and Sule Apraş Bilgen¹, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²HACETTEPE UNIVERSITY, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) patients have a higher risk of venous thromboembolism (VTE) [1]. We aimed to assess the incidence of thrombosis and associated…
Abstract Number: 0008 • ACR Convergence 2021
Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients
Erin Wilfong, Alberto Cisneros, Jennifer Young-Glazer, Scott Smith, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Anti-tRNA synthetase syndrome (ARS) is a severe systemic autoimmune disease associated with myositis, interstitial lung disease, rash, and arthritis. ARS is associated with autoantibodies…
Abstract Number: 0699 • ACR Convergence 2021
Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review
Lilian Vilar, William Moore and Ian Ward, Dwight D Eisenhower Army Medical Center, Fort Gordon
Background/Purpose: The Idiopathic Inflammatory myopathies (IIM) are characterized by muscle damage and progressive weakness. Myoglobin is not typically released in high levels in IIM and…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 0330 • ACR Convergence 2021
Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)
Thaisa Cotton¹, Marvin Fritzler², May Choi³, Boyang Zheng⁴, Omid Zahedi Niaki⁵, Louis-Pierre Grenier⁵, Evelyne Vinet⁶, Christian Pineau¹, Luck Lukusa⁷, Fares Kalache⁵ and Sasha Bernatsky¹, ¹McGill University, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University Health Centre, Mont Royal, QC, Canada, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
Abstract Number: 0700 • ACR Convergence 2021
Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review
David Mecham¹, William Moore¹ and Ian Ward², ¹Dwight D Eisenhower Army Medical Center, Fort Gordon, ²United States Army, Evans, GA
Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) are often difficult to treat, require chronic steroid therapy, and can remain active despite multiple treatment regimens. The objective…
Abstract Number: 0721 • ACR Convergence 2021
Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis
saikumar dunga¹, Chengappa Kavadichanda² and VirSingh Negi³, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
Background/Purpose: Manual muscle testing (MMT) and Functional index 2(FI-2) are the usual methods in assessing disease activity and functional status in IIM1. Limitations of MMT8…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0702 • ACR Convergence 2021
Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing
Sarvar Nazir¹, Lisa Rider², Ira Targoff³, Stanley Naides⁴, Andrew Mammen⁵, Steven Greenberg⁶ and Adam Schiffenbauer⁵, ¹NIEHS, NIH, Bethesda, MD, ²NIEHS, NIH, Garrett Park, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Self, Dana Point, CA, ⁵National Institutes of Health, Bethesda, MD, ⁶Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
Abstract Number: 0722 • ACR Convergence 2021
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Alexandrine Mahoudeau¹, Céline Anquetil², Nozomu Tawara¹, Hossein Khademian¹, Damien Amelin¹, Yves Allenbach³ and Olivier Benveniste³, ¹Center of Research in Myology, Sorbonne University, Paris, France, ²Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France
Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
Abstract Number: 0442 • ACR Convergence 2021
Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
Kenichi Uto¹, Koji Ueda², Takaichi Okano¹, Kengo Akashi¹, Soshi Takahashi³, Yuji Nakamachi⁴, Takamitsu Imanishi¹, Seiji Kawano¹, Yoshihiko Yano⁵ and Jun Saegusa⁶, ¹Kobe University Hospital, Kobe, Japan, ²Japanese Foundation for Cancer Research, Tokyo, Japan, ³Shinko Hospital, Kobe, Japan, ⁴Kobe University School of Medicine, Kobe, Japan, ⁵Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, ⁶Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan
Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.